A method for preparing a mesoporous polydopamine nanodiagnostic agent for MRI-visualized cancer treatment
Patent Information
- Application Number
- CN202311848183.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-12-29
AI Technical Summary
Existing MRI contrast agents have problems of high toxicity and low sensitivity, which is difficult to meet clinical needs, and the inflammatory response caused by photothermal treatment increases the risk of cancer recurrence.
Mesoporous nanoparticles are prepared by doping gadolinium ions and arginine into polydopamine, and loading the anti-inflammatory drug meloxicam to form MX@Arg-Gd-MPDA nanodiagnostic agents to achieve T1-T2 dual-mode MRI Imaging and photothermal therapy.
It improves the encapsulation and delivery efficiency of drugs, enhances the photothermal conversion and antioxidant performance, reduces the risk of cancer recurrence, and improves the accuracy and safety of cancer treatment.
Smart Images

Figure CN117797273B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of magnetic resonance imaging, and in particular relates to a method for preparing a mesoporous polydopamine nano-diagnostic agent for MRI visualized cancer treatment. Background Art
[0002] Magnetic resonance imaging (MRI) is widely used due to its advantages in clinical disease diagnosis, such as strong soft tissue contrast and high spatial resolution. Its basic principle is to place the patient in a special magnetic field and stimulate the resonance of hydrogen nuclei in the body by applying radio frequency pulses. After the radio frequency pulse stops, the hydrogen nuclei emit signals at a specific frequency and release energy, which are processed by electronic computers to form magnetic resonance images. When human tissues are lesioned, the transverse and longitudinal relaxation times of hydrogen nuclei change, resulting in changes in MRI images, which can infer the location of the lesion or the damage. In the diagnosis of some diseases, such as cancer, contrast agents are usually required to shorten the relaxation time of surrounding water protons, thereby enhancing tissue contrast and improving the sensitivity and accuracy of MRI. MRI contrast agents are generally divided into two categories. One is the T1 contrast agent that shortens the longitudinal relaxation time of protons, mainly including Gd-DTPA, Mn-DPDP, etc., which are commonly used in clinical practice. They present brighter signals in T1-weighted imaging. The other type is T2 contrast agents that shorten the transverse relaxation time of protons, mainly including superparamagnetic iron oxides (SPIOs), which present darker signals in T2-weighted imaging. However, these contrast agents currently used have problems such as high toxicity and low sensitivity, and are difficult to meet clinical needs. Therefore, there is an urgent need to develop new, safer and more sensitive contrast agents.
[0003] In recent years, the construction of nano drug delivery systems with MRI contrast function has become a research hotspot, which has shown broad application prospects in monitoring the progress of treatment and improving the accuracy of treatment. For example, manganese carbonate@polydopamine (MnCO3@PDA) core-shell nanocomposites are used for MRI-guided photothermal therapy (PTT) treatment, while chitosan-derived glycolipid nanoparticles are used for MRI-guided photodynamic therapy (PDT) treatment. These nano drug delivery systems show more sensitive contrast effects than commercial contrast agents and achieve ideal tumor inhibition under the guidance of MRI. In addition, the continuous development of nanotechnology has provided new possibilities for the development of T1-T2 dual-mode MRI contrast agents, which can meet the needs of different tissues for T1 / T2 weighted imaging, thereby further improving the accuracy of disease diagnosis. At present, the development of T1-T2 dual-mode contrast agents mainly adopts two strategies: one strategy is to combine T1 contrast agents with T2 contrast agents to construct new composite contrast agents. During imaging, the two exert their respective contrast capabilities, presenting T1-T2 dual-mode contrast as a whole. For example, gadolinium-labeled magnetite nanoparticles, core / shell / shell structured ferroferric oxide / silicon dioxide / gadolinium carbonate nanoparticles, etc. Another strategy is to change the spatial conformation around the metal ions so that they affect the transverse and longitudinal resonance of protons at the same time, thereby shortening the relaxation time and achieving the effect of T1-T2 dual-mode contrast. For example, a new composite nanosystem based on gadolinium-doped polydopamine nanoions and metal-organic framework structure (Gd-PDA-Ce6@Gd-MOF, GPCG). Benefiting from the metal-organic framework (MOF) structure, GPCG has the ability of T1-T2 dual-mode MRI contrast.
[0004] Photothermal therapy (PTT) is an emerging treatment method that has been widely studied. It achieves tumor ablation by converting light energy into heat energy. It has the advantages of less trauma, low toxicity and high efficiency, and is therefore considered a promising treatment strategy. However, studies have shown that after PTT induces cancer cell necrosis, the release of intracellular components into the extracellular environment will trigger an inflammatory response. The inflammatory factors produced by this process may activate pro-survival genes in residual cancer cells and increase the risk of cancer recurrence. Therefore, it has become necessary to explore anti-inflammatory and photothermal combined treatment strategies to alleviate the inflammatory response caused by photothermal therapy. The development of nanomaterials provides a feasible strategy for achieving combined therapy. Combining photothermal converters with anti-inflammatory drugs to construct multifunctional nanoformulations has become an effective way to solve the above problems.
[0005] As an artificial melanin material, polydopamine (PDA) has excellent biocompatibility, metal chelation, free radical scavenging and photothermal conversion capabilities. It is formed by the self-polymerization of dopamine in an alkaline environment. Nanomaterials prepared based on PDA have been widely used in the fields of bioimaging, drug delivery, etc. In particular, its ability to chelate metals and its good compatibility in vivo. By combining PDA with other functional components, it is possible to integrate multiple therapeutic and imaging functions, providing a more comprehensive and effective solution for cancer treatment and diagnosis. It can be seen that the development based on PDA not only shows a wide range of application prospects in the biomedical field, but also has important potential value in constructing T1-T2 dual-mode MRI contrast agents with both photothermal and anti-inflammatory cancer treatment effects. Summary of the invention
[0006] In order to overcome the deficiencies of the above-mentioned prior art, the present invention provides a method for generating nanoparticles by doping gadolinium and arginine into polydopamine and loading the drug meloxicam (MX). By doping with gadolinium ions and arginine, the nanoparticles not only have the ability of T1-T2 dual-mode imaging, but also have enhanced photothermal performance and antioxidant properties.
[0007] To achieve the above object, the present invention is implemented by the following technical solutions:
[0008] The first aspect of the present invention provides a method for preparing a mesoporous polydopamine nanodiagnostic agent, comprising the following steps:
[0009] S1. dissolving dopamine hydrochloride and gadolinium trichloride hexahydrate in water, and stirring in the dark to prepare a dopamine-gadolinium chelate solution;
[0010] S2, adding the surfactant F127 and the dopamine-gadolinium chelate solution of step S1 to the mixed solution of ethanol-water, and stirring in the dark until mixed;
[0011] S3, add 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasound, and continue ultrasonic dispersion until milky white;
[0012] S4. Add arginine (Arg) solution under stirring, and stir to mix well in the dark;
[0013] S5, centrifuging, resuspending and washing the solution stirred in step S4 to prepare Arg-Gd-MPDA (AGM) nanoparticles;
[0014] S6. Disperse the Arg-Gd-MPDA (AGM) nanoparticles of step S4 in water, mix and stir with the DMSO solution of meloxicam (MX), collect the precipitate, wash and remove DMSO, and obtain MX@Arg-Gd-MPDA (MAGM) nano-diagnostic agent.
[0015] The present invention uses Gd 3+ The MAGM nanoformulation was prepared by using MPDA nanoparticles doped with Arg as carriers and loading the anti-inflammatory drug MX, thereby achieving photothermal and anti-inflammatory treatment of cancer under the guidance of T1-T2 dual-mode MRI, improving the efficiency of cancer treatment and reducing the risk of recurrence. First, the mesoporous nanostructure greatly improves the encapsulation and delivery efficiency of the drug, which is of great significance for the prolonged retention and slow release of the drug. Secondly, the doping of arginine enhances the free radical scavenging and photothermal conversion performance of the polydopamine material, which is beneficial to improving the efficiency of disease treatment. Thirdly, the chelated Gd 3+ MAGM has the potential to be used as a T1-T2 dual-mode MRI contrast agent under its mesoporous spatial structure, providing stronger support for MRI-guided cancer treatment.
[0016] As a preferred embodiment of the present invention, in step S1, the mass ratio of dopamine hydrochloride to gadolinium chloride hexahydrate is 20-25:1.
[0017] As a preferred embodiment of the present invention, in step S1, the parameters of light-proof stirring are 150-200 rpm and 22-26 h.
[0018] As a preferred embodiment of the present invention, in step S1, the mass volume ratio of gadolinium trichloride hexahydrate to water is 1 mg:1-1.5 mL.
[0019] As a preferred embodiment of the present invention, in step S2, the mass volume ratio of the F127 to the dopamine-gadolinium chelate solution is 100-150 mg:1 mL.
[0020] As a preferred embodiment of the present invention, in step S2, the parameters of light-shielded stirring are 150-200 rpm and 15-25 min.
[0021] As a preferred embodiment of the present invention, in step S2, the volume ratio of the ethanol-water mixed solution to the dopamine-gadolinium chelate solution is 40:1-1.2.
[0022] As a preferred embodiment of the present invention, in step S3, the ultrasonic parameters are: 4kHz, 2 to 5min.
[0023] As a preferred embodiment of the present invention, in step S4, the concentration of the arginine solution is 17-19 mg / mL, and the parameters of stirring in the dark are 150-200 rpm for 6-8 hours.
[0024] As a preferred embodiment of the present invention, in step S5, the washing solvent is ethanol or ultrapure water.
[0025] As a preferred embodiment of the present invention, in step S6, the volume ratio of the Arg-Gd-MPDA (AGM) aqueous solution to the meloxicam (MX) DMSO solution is 1:1.
[0026] The second aspect of the present invention provides a mesoporous polydopamine nano-diagnostic and therapeutic agent prepared by the preparation method described in the first aspect.
[0027] The third aspect of the present invention provides the use of the mesoporous polydopamine nano-diagnostic and therapeutic agent described in the second aspect in the preparation of a contrast agent.
[0028] The third aspect of the present invention provides the use of the mesoporous polydopamine nano-diagnostic and therapeutic agent described in the second aspect in the preparation of anti-tumor drugs.
[0029] As a preferred embodiment of the present invention, the anti-tumor drug is an anti-breast cancer drug.
[0030] Compared with the prior art, the present invention has the following beneficial effects:
[0031] The invention discloses a method for preparing a mesoporous polydopamine nano-diagnostic agent, using gadolinium ions (Gd 3+ ) and arginine (Arg) doped mesoporous polydopamine (MPDA) nanoparticles are used as carriers to load the anti-inflammatory drug meloxicam (MX) to prepare the nanoformulation MX@Arg-Gd-MPDA (MAGM), which is used for T1-T2 dual-mode MRI-guided cancer photothermal and anti-inflammatory treatment. In general, the present invention has the following advantages:
[0032] (1) In order to solve the problem of low photothermal performance and limited antioxidant performance of polydopamine nanoparticles, the present invention doped arginine into mesoporous polydopamine to construct a donor-acceptor microstructure inside it, reduce the energy band gap, and promote the electron transfer process, thereby enhancing the near-infrared light absorption and photothermal conversion performance of polydopamine; at the same time, it destroys the effective inter-unit π conjugation in polydopamine to form weak aggregates, thereby increasing the concentration of internal free radicals and enhancing the free radical scavenging effect.
[0033] (2) To address the problem of the influence of MRI artifacts existing in single-mode magnetic resonance imaging on the diagnostic results, the present invention adopts the method of doping Gd in mesoporous polydopamine. 3+, and then realize T1-T2 dual-modality magnetic resonance imaging, making MRI imaging results more accurate and statistically significant.
[0034] (3) The nanoformulation prepared by the present invention has good biocompatibility, tumor microenvironment responsiveness and drug sustained release ability, which can effectively avoid the problems of conventional drugs such as large side effects, poor targeting and short circulation time in the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 The diagram of the changes in the mixed solution during the preparation of MAGM nanoparticles (1 is a mixed solution of dopamine-gadolinium chelate and F127 dispersed in ethanol and water, 2 is the solution after adding TMB, 3 is the solution after adding arginine, and 4 is the MAGM dispersion);
[0036] Figure 2 Transmission electron microscopy image (A) and particle size distribution diagram (B) of MAGM nanoparticles;
[0037] Figure 3 is the EDS spectrum of MAGM nanoparticles;
[0038] Figure 4 (A) Heating conditions of different samples (808nm, 1W / cm 2 , 100 μg / mL); MAGM at different concentrations (808 nm, 1 W / cm 2 ) and (C) temperature rise under different powers (808 nm, 100 μg / mL); (D) photothermal conversion efficiency of MAGM (808 nm, 1 W / cm 2 , 100 μg / mL);
[0039] Figure 5 The temperature variation curve of MAGM (808nm, 1W / cm 2 , 100 μg / mL);
[0040] Figure 6 (A) DPPH radical scavenging rate of GM, AGM and MAGM (20 μg / mL) within 20 minutes; (B) UV-visible absorption spectra of the solution after treatment with GM, AGM and MAGM (100 μg / mL);
[0041] Figure 7 (A) T1- and (B) T2-weighted magnetic resonance imaging of AGM and Gd-DTPA; (C) longitudinal and (D) transverse relaxation rates of AGM and Gd-DTPA (field strength = 3T);
[0042] Figure 8(A) T1- and (B) T2-weighted magnetic resonance imaging of AGM and Gd-DTPA; (C) longitudinal and (D) transverse relaxation rates of AGM and Gd-DTPA (field strength = 7T);
[0043] Fig. 9 The survival rate of 4T1 cells after treatment under different conditions (NIR: 808nm, 1W / cm 2 , 3min); at the same concentration, from left to right they represent MX, AGM, MAGM, AGM+NIR, and MAGM+NIR. DETAILED DESCRIPTION
[0044] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0045] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0046] Example 1 Preparation method of a mesoporous polydopamine nanodiagnostic agent (MX@Arg-Gd-MPDA)
[0047] Arg-Gd-MPDA (AGM) nanocarriers were prepared by chelating gadolinium ions in mesoporous polydopamine and doping with arginine, and then loaded with the anti-inflammatory drug meloxicam (MX) to prepare MX@Arg-Gd-MPDA (MAGM) nanotherapeutic agents.
[0048] The specific method is as follows:
[0049] 1. The preparation method of the gadolinium and arginine doped mesoporous polydopamine Arg-Gd-MPDA (AGM) comprises the following steps:
[0050] (1) dissolving dopamine hydrochloride and gadolinium chloride hexahydrate in ultrapure water and stirring in the dark (180 rpm, 24 h) to obtain a dopamine-gadolinium chelate solution; the mass ratio of dopamine hydrochloride to gadolinium chloride hexahydrate is 23:1; the mass volume ratio of gadolinium chloride hexahydrate to ultrapure water is 1 mg:1-1.3 mL;
[0051] (2) adding the surfactant F127 and the dopamine-gadolinium chelate solution of step (1) to a mixed solution of anhydrous ethanol and ultrapure water (volume ratio of 1:1), stirring in the dark until mixed (stirring parameters are 180 rpm, 20 min); the mass volume ratio of F127 to the dopamine-gadolinium chelate solution is 120 mg:1 mL; the volume ratio of the anhydrous ethanol-ultrapure water mixed solution to the dopamine-gadolinium chelate solution is 40:1.1;
[0052] (3) adding 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasound, and continuing ultrasonic dispersion until milky white (4 kHz, 3 min), the volume ratio of TMB to the mixed solution of step (2) being 41:1;
[0053] (4) adding arginine (Arg) aqueous solution (18 mg / mL) dropwise under magnetic stirring, stirring and mixing in the dark (180 rpm, 7 h), the volume ratio of arginine aqueous solution to the mixed solution in step (3) being 12.6:1;
[0054] (5) Finally, the obtained solution was divided into centrifuge tubes and centrifuged (13000 rpm, 10 min). The obtained precipitate was resuspended in anhydrous ethanol and washed by water bath ultrasound (4 kHz, 28 min). The washing was repeated twice. The obtained product was AGM (Arg-Gd-MPDA) nanoparticles. At the same time, in step (4), tris (hydroxymethylaminomethane) (Tris) solution (20 mg / mL) was used to replace the Arg solution. The same steps were used to prepare and centrifuge and wash to obtain Gd-MPDA (GM) for subsequent experimental control.
[0055] 2. The preparation method of nanoparticles MX@Arg-Gd-MPDA (MAGM) loaded with the anti-inflammatory drug meloxicam (MX) is as follows:
[0056] (6) The product AGM obtained in step (5) was dispersed in pure water (1 mg / mL), mixed with a DMSO solution of MX (1 mg / mL) (the volume ratio of the two solutions was 1:1), and stirred for 24 hours. The solution after the reaction was divided into centrifuge tubes, and the precipitate was collected by centrifugation (13000 rpm, 10 min). The precipitate was washed with anhydrous ethanol and ultrapure water to remove DMSO, and then resuspended and collected with ultrapure water to obtain MAGM nanoparticles.
[0057] Example 2 Characterization of Mesoporous Polydopamine Nanotheranostic Agent (MAGM)
[0058] (1) Color change of mixed solution during the preparation of MAGM nanoparticles
[0059] like Figure 1As shown, dopamine-gadolinium chelate and F127 are dispersed in a mixed solution of ethanol and water to form a white transparent solution; after TMB is gradually added under water bath ultrasound, the solution gradually turns milky white; after the arginine solution is added, the dopamine polymerization reaction liquid turns gray due to the alkaline environment provided by the arginine solution; after 8 hours of reaction, a black nanoparticle dispersion is formed, and the product AGM nanoparticles can be obtained after centrifugal washing; the product AGM is mixed and stirred with MX, and then centrifuged and washed and collected to obtain a MAGM dispersion of a black solution.
[0060] (2) Characterization of MAGM morphology and particle size
[0061] Take 10 μL of the diluted MAGM dispersion (50 μg / mL) and drop it on the front of the carbon support film copper mesh. After natural air drying in a desiccator at room temperature, use a transmission electron microscope (TEM) to observe the microscopic morphology (morphology, particle size and dispersion) of MAGM under a voltage of 200 KV. Figure 2 As shown in A, the prepared MAGM particle size distribution range is narrow, spherical, uniform in size, about 200nm, and presents a uniformly distributed mesoporous structure. At the same time, the prepared MAGM nanoparticles were resuspended in ultrapure water, diluted to a certain concentration (50μg / mL) and then ultrasonically homogenized. The hydrated particle size, polydispersity coefficient and Zeta potential of the nanoparticle sample were detected by dynamic light scattering (DLS). As shown in Table 1, Figure 2 As shown in Figure B, MAGM nanoparticles have good dispersibility and a hydrated particle size of about 247 nm. The reason why the results of transmission electron microscopy and dynamic light scattering (DLS) are different is that the latter obtains the particle size of the nanoparticles in the hydrated state, and the solvent effect makes the nanoparticles show a larger hydrodynamic volume.
[0062] (3) EDS energy spectrum analysis and ICP-AES characterization
[0063] The MAGM nanoparticles were diluted (50 μg / mL) and fully dispersed by ultrasonication. 10 μL of the solution was dropped onto a copper mesh. After drying, the distribution of the four elements carbon (C), oxygen (O), nitrogen (N), and Gd in MAGM was determined by X-ray energy dispersive spectrometry (EDS) under a 200 kV transmission electron microscope. At the same time, 1 mL of MAGM solution (1 mg / mL) was added with an appropriate amount of concentrated nitric acid (2-4 mL), and heated in an oil bath for more than 48 h until the solution became colorless. The solution was diluted with ultrapure water and the volume was adjusted to 10 mL (acid content <5%, wt%). The content of Gd element in MAGM nanoparticles was determined by inductively coupled plasma-atomic emission spectroscopy (ICP-AES). Figure 3As shown, the four elements C, N, O, and Gd are evenly distributed in the nanoparticles, and the Gd content is 3.06% (wt%) as determined by ICP-AES. The successful chelation of Gd provides a basis for the use of MAGM in MRI angiography. In addition, through the quantitative analysis of the N element, the doping amount of Arg in MAGM is calculated to be 3.22% (wt%).
[0064] (4) Study on the in vitro photothermal properties of MAGM using 808 nm near-infrared laser
[0065] The photothermal conversion efficiency and photothermal stability of MAGM were investigated. 1) Comparison of the photothermal conversion performance of different samples: 2 mL of ultrapure water, GM, AGM and MAGM (100 μg / mL) were subjected to 1 W / cm 2 1) 2 mL of MAGM samples with different concentrations (50, 100 and 150 μg / mL) were irradiated with a near-infrared laser and the real-time temperature of the solution was recorded within 10 min. 2) The effect of concentration on temperature rise was investigated by 1 W / cm 2 Near-infrared laser irradiation was used to record the real-time temperature of the solution within 10 min. 3) The effect of laser power on temperature rise was investigated: 2 mL of MAGM (100 μg / mL) sample was exposed to different powers (0.5, 1, and 1.5 W / cm 2 ) Near-infrared laser irradiation, record the real-time temperature of the solution within 10 minutes; 4) Photothermal conversion efficiency study: 2mL of MAGM (100μg / mL) sample was subjected to 1W / cm 2 Near-infrared laser irradiation was performed until the temperature was stable (the temperature did not change within 2 minutes), and then naturally cooled. The real-time temperature of the whole process of heating and cooling was recorded, and the photothermal conversion efficiency of MAGM was calculated; 5) Photothermal stability study: 2 mL of 100 μg / mL MAGM sample was subjected to 1 W / cm 2 Near-infrared laser irradiation lasted for 15 minutes, and then the irradiation was stopped and the solution temperature was allowed to drop to the initial temperature. This was considered a cycle. MAGM was subjected to four cycles and the real-time temperature of the whole process was recorded to study the photothermal stability of MAGM.
[0066] The results are as follows Figure 4 As shown in Figure A, the temperature of the AGM group doped with Arg increased by 34°C, which was higher than that of the GM group not doped with Arg (22°C), proving that the doping of Arg further improved the photothermal conversion performance of polydopamine, and its photothermal conversion efficiency could reach 56.5% ( Figure 4 D), the reason may be that Arg destroyed the dense microstructure of polydopamine, constructed a donor-acceptor structure inside it, promoted electron transfer, and reduced non-thermal radiation transitions. Then, the factors affecting the heating effect of MAGM were studied by changing the concentration and laser power. The results are as follows Figure 4As shown in Figures B and 4C, the heating effect of MAGM increases with the increase of concentration and power. Therefore, in practical applications, the sample concentration, irradiation power and time can be adjusted according to different temperature requirements to achieve the best effect. In addition, the photothermal stability of MAGM was evaluated by the cyclic heating and cooling process ( Figure 5 ), after 4 cycles, the maximum temperature only dropped by 1.6°C, which proves that cyclic irradiation does not significantly affect the photothermal conversion ability of MAGM, has photothermal stability, and will have broad application prospects in PTT.
[0067] (5) In vitro free radical scavenging performance study
[0068] The free radical scavenging performance of GM, AGM and MAGM was evaluated by the DPPH method and the salicylic acid method (the evaluation operation of the DPPH method is specifically referred to the literature "Adolfsson KH, Huang P, Golda-Cepa M, et al. Scavenging of DPPH by Persistent Free Radicals in Carbonized Particles [J]. Advanced Sustainable Systems, 2023, 7 (3): 2200425."; the evaluation operation of the salicylic acid method is specifically referred to the literature "Peralta E, Roa G, Hernandez-Servin JA, et al. Hydroxyl Radicals quantification by UVspectrophotometry [J]. Electrochimica Acta, 2014, 129: 137-141."). Figure 6 As shown in the figure, all three have the ability to scavenge DPPH and ·OH. The free radicals in the GM group are lower, and the AGM doped with arginine shows a better scavenging ability. This is because the incorporated arginine destroys the dense microstructure inside polydopamine and forms weak polymers with stronger free radical capture ability. MAGM shows a similar free radical scavenging rate to AGM, indicating that the loading of MX does not affect the capture of free radicals by nanoparticles.
[0069] (6) In vitro magnetic resonance imaging capability
[0070] The T1- and T2-weighted MRI contrast abilities of AGM and Gd-DTPA (Magnevist) contrast agents were compared using a clinically used 3T MRI. Figure 7 ), AGM showed better imaging ability than Gd-DTPA, with an r1 value of 74.86 mM -1 ·s -1) is much higher than Gd-DTPA (4.99mM-1·s -1 ), which is due to the fact that the Gd3+ chelated mesoporous nanoparticles significantly affect the relaxation of water molecules. This effect on the relaxation of water molecules also makes AGM have a higher r2 (70.66mM -1 ·s -1 ), and also showed excellent results in T2-weighted imaging ( Figure 7 ), while the r2 value of Gd-DTPA is only 4.82mM -1 ·s -1 , and cannot be used for T2 angiography. 3+ AGM has a higher T1 sensitivity than Gd-DTPA, and also has T1-T2 dual-mode imaging capability, which is of great significance for improving the accuracy of disease diagnosis and treatment. At the same time, in order to further study the application prospects of AGM as a T1-T2 dual-mode MRI contrast agent in ultra-high field strength magnetic resonance imaging, the imaging performance of AGM at 7T field strength was also evaluated. In T1-weighted imaging, AGM showed better imaging effect than Gd-DTPA ( Figure 8 ). Compared with the experimental results under 3T field strength, the r1 value of AGM is reduced to 9.76mM -1 ·s -1 , but still higher than Gd-DTPA (4.63mM -1 ·s -1 The reason for the decrease in relaxation rate is that as the field strength increases, the interaction between AGM and water molecules changes, limiting the longitudinal relaxation process of water molecules. However, as a small molecule, Gd-DTPA is less affected by the field strength and the relaxation rate does not decrease significantly. In addition, AGM also shows T2 imaging ability at a field strength of 7T ( Figure 8 ) and has a higher r2(121.77mM -1 ·s -1 ), which can be considered as an excellent T2 contrast agent at ultra-high field strength. In summary, AGM also has a high-sensitivity T1-T2 dual-mode MRI contrast capability at a field strength of 7T, further broadening its application prospects in the field of magnetic resonance imaging.
[0071] (7) Cytotoxicity studies
[0072] The photothermal anticancer effect of MAGM was studied at the level of mouse breast cancer cells (4T1). 4T1 cells were cultured in 96-well plates (5000 cells / well, 24h), and the effects of MX, AGM, and MAGM on the survival rate of 4T1 cells with or without laser irradiation were detected by CCK8 experiments. Fig. 9The results show that the three nanoparticles have no obvious toxicity to cells, which reflects the good biocompatibility of nanoparticles. 2 , 3min) to evaluate the effect of photothermal therapy. The cell survival rates of the two groups showed a similar downward trend. When the concentration was 100μg / mL, the survival rate dropped to about 50%. When the concentration continued to increase to 200μg / mL, the survival rate was only about 15%. This proves that the photothermal therapy of AGM and MAGM has a significant killing effect on 4T1 cells.
[0073] In summary, the present invention uses gadolinium ions and arginine-doped mesoporous polydopamine to prepare Arg-Gd-MPDA (AGM) nanocarriers, and then loads the anti-inflammatory drug meloxicam (MX) to prepare MX@Arg-Gd-MPDA (MAGM) nano-diagnostic and therapeutic agents, so that the nano-diagnostic and therapeutic agents not only have the ability of T1-T2 dual-mode imaging, but also have enhanced photothermal and antioxidant properties, which provides more powerful support for MRI-guided cancer treatment and has important potential application value.
[0074] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.
Claims
1. Use of a mesoporous polydopamine nanodiagnostic agent in the preparation of a contrast agent and / or an anti-tumor drug, characterized in that: The preparation method of the mesoporous polydopamine nano-diagnostic agent comprises the following steps: S1. dissolving dopamine hydrochloride and gadolinium trichloride hexahydrate in water, and stirring in the dark to prepare a dopamine-gadolinium chelate solution; S2, adding the surfactant F127 and the dopamine-gadolinium chelate solution of step S1 to the mixed solution of ethanol-water, and stirring in the dark until mixed; S3, add 1,3,5-trimethylbenzene solution while shaking in a water bath ultrasound, and continue to disperse by ultrasound until milky white; S4. Add arginine solution under stirring, and stir to mix evenly in the dark; S5, centrifuging, resuspending and washing the solution stirred in step S4 to prepare Arg-Gd-MPDA nanoparticles; S6. Disperse the Arg-Gd-MPDA nanoparticles of step S4 in water, mix and stir with the DMSO solution of meloxicam, collect the precipitate, and wash to remove DMSO to obtain the MX@Arg-Gd-MPDA nano-diagnostic agent.
2. The use according to claim 1, characterized in that: In step S1, the mass ratio of dopamine hydrochloride to gadolinium chloride hexahydrate is 20-25:
1.
3. The use according to claim 1, characterized in that: In step S1, the mass volume ratio of gadolinium trichloride hexahydrate to water is 1 mg:1-1.5 mL.
4. The use according to claim 1, characterized in that: In step S2, the mass volume ratio of the F127 to the dopamine-gadolinium chelate solution is 100-150 mg:1 mL.
5. The use according to claim 1, characterized in that: In step S2, the volume ratio of the ethanol-water mixed solution to the dopamine-gadolinium chelate solution is 40:1-1.
2.
6. The use according to claim 1, characterized in that: In step S4, the concentration of the arginine solution is 17-19 mg / mL, and the parameters of stirring in the dark are 150-200 rpm for 6-8 hours.
7. The use according to claim 1, characterized in that: In step S6, the volume ratio of the Arg-Gd-MPDA aqueous solution to the meloxicam DMSO solution is 1:1.
Citation Information
Patent Citations
Preparation method for Gd2O3 nanoparticle controllably surface-modified by dopamine and used for positive reinforcement of MRI radiography
CN103920167A
Polydopamine nano diagnosis and treatment agent and preparation method thereof
CN109364245A
Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging
CN112759762A
PEOz and polydopamine-gadolinium ion network modified degradable mesoporous silicon nano drug delivery system and preparation method thereof
CN113577277A
Bionic nano diagnosis and treatment agent for high-field magnetic resonance imaging and preparation method of bionic nano diagnosis and treatment agent
CN114225055A
